Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 3/20 | 0.46 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.42 |
| ▸ | MTOR | P42345 | 1/20 | 0.42 |
| ▸ | PRKDC | P78527 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
| ▸ | BTK | Q06187 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3376049 | 1.00 | MTNR1A (0.46) | MTNR1AMTNR1BROCK2KCNH2SLC2A1 | |
| SCHEMBL3376051 | 1.00 | MTNR1A (0.46) | MTNR1AMTNR1BROCK2KCNH2SLC2A1 | |
| SCHEMBL3410549 | 1.00 | MTNR1A (0.46) | MTNR1AMTNR1BROCK2KCNH2SLC2A1 | |
| SCHEMBL3375560 | 0.88 | MTNR1B (0.50) | MTNR1AMTNR1BPIK3CAMTORPRKDC | |
| SCHEMBL3375559 | 0.88 | MTNR1B (0.50) | MTNR1AMTNR1BPIK3CAMTORPRKDC | |
| SCHEMBL3374498 | 0.82 | KCNH2 (0.44) | MTNR1AMTNR1BKCNH2SLC2A1JAK2 | |
| SCHEMBL2537288 | 0.82 | KCNH2 (0.44) | MTNR1AMTNR1BKCNH2SLC2A1JAK2 | |
| SCHEMBL3374492 | 0.82 | KCNH2 (0.44) | MTNR1AMTNR1BKCNH2SLC2A1JAK2 | |
| SCHEMBL2537286 | 0.82 | KCNH2 (0.44) | MTNR1AMTNR1BKCNH2SLC2A1JAK2 | |
| SCHEMBL5777153 | 0.80 | MTNR1A (0.46) | MTNR1AMTNR1BKCNH2SLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1987040-B1 | ETHANOL OR 1,2-ETHANEDIOL CYCLOHEXYL ANTIBIOTIC DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2010-11-10 | — | — | EP | disclosed |
| US-7820655-B2 | Ethanol or 1,2-ethanediol cyclohexyl antibiotic derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-10-26 | — | — | US | disclosed |
| US-20090005368-A1 | such as 6-({trans-4-[(1R)-1-hydroxy-2-(3-methoxy-quinolin-5-yl)-ethyl]-cyclohexylamino}-methyl)-4H-pyrido[3,2-b][1,4]thiazin-3-one for treating infections from Streptococcus pneumoniae, Haemophilus influenzae, Moraxella, Staphylococcus, Enterococcus | ACTELION PHARMACEUTICALS LTD. (CH) | 2009-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005368-A1 | such as 6-({trans-4-[(1R)-1-hydroxy-2-(3-methoxy-quinolin-5-yl)-ethyl]-cyclohexylamino}-methyl)-4H-pyrido[3,2-b][1,4]thiazin-3-one for treating infections from Streptococcus pneumoniae, Haemophilus influenzae, Moraxella, Staphylococcus, Enterococcus | RBPJ, RXRA, MRPL21 | MTNR1A 50/4885MTNR1B 57/4885ROCK2 1404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.